Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)
Document Type
Article
Publication Date
7-26-2023
Publication Title
European Urology Focus
Abstract
EA8212 BRIDGE is a phase 3 randomized trial comparing BCG vs GemDoce for BCG naïve high-risk non-muscle-invasive bladder cancer. This article provides an explanation for the rationale of the clinical trial and details the study design.
PubMed ID
37422371
Recommended Citation
Kates, Max; Chu, Xiangying; Hahn, Noah; Pietzak, Eugene; Smith, Angela; Shevrin, Daniel H.; Crispen, Paul; Williams, Stephen B.; Daneshmand, Siamak; Packiam, Vignesh T.; Porten, Sima; Westerman, Mary E.; Wagner, Lynne I.; and Carducci, Michael, "Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)" (2023). School of Medicine Faculty Publications. 1296.
https://digitalscholar.lsuhsc.edu/som_facpubs/1296